Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 410 results for stroke

  1. Smoking: support and treatment for people with long term conditions (IND157)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM127

  2. Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

    Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

  3. Smoking: support and treatment for people with long-term conditions or SMI (IND98)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM39

  4. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  5. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  6. Alcohol use: brief intervention for people with a long-term condition (IND202)

    This indicator covers the percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM181

  7. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  8. Interim methods guide for developing service guidance 2014 (PMG8)

    This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance

  9. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  10. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  11. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  12. Biggest shake-up in type 2 diabetes care in a decade announced

    Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.

  13. Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes

    Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.

  14. 'Artificial pancreas' transforming the lives of thousands of children and young people with type 1 diabetes

    The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.

  15. Fostering the digital health tech revolution

    Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.